Non-Ras targets of farnesyltransferase inhibitors: focus on Rho View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1998-09

AUTHORS

Peter F Lebowitz, George C Prendergast

ABSTRACT

Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals. More... »

PAGES

1439

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.onc.1202175

DOI

http://dx.doi.org/10.1038/sj.onc.1202175

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025114095

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9779989


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Actins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkyl and Aryl Transferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Adhesion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Transformed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endothelial Growth Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Farnesyltranstransferase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "GTP-Binding Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factor A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ras Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "rhoB GTP-Binding Protein", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wistar Institute", 
          "id": "https://www.grid.ac/institutes/grid.251075.4", 
          "name": [
            "The Wistar Institute, Philadelphia, Pennsylvania 19104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebowitz", 
        "givenName": "Peter F", 
        "id": "sg:person.0645204112.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645204112.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wistar Institute", 
          "id": "https://www.grid.ac/institutes/grid.251075.4", 
          "name": [
            "The Wistar Institute, Philadelphia, Pennsylvania 19104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prendergast", 
        "givenName": "George C", 
        "id": "sg:person.0651643165.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651643165.04"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-09", 
    "datePublishedReg": "1998-09-01", 
    "description": "Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.onc.1202175", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Non-Ras targets of farnesyltransferase inhibitors: focus on Rho", 
    "pagination": "1439", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "77a4f9ed3a6c919e3b9316677e8ebdff7fd98240e4bcac876681c6a4c41c3ce6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9779989"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8711562"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.onc.1202175"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025114095"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.onc.1202175", 
      "https://app.dimensions.ai/details/publication/pub.1025114095"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000360_0000000360/records_118309_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/1202175"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1202175'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      20 PREDICATES      47 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.onc.1202175 schema:about N07e02c34f74b48b8b20c7592cfa4fd42
2 N1e1c045b5cef4ddb8c8d2ccf9826b264
3 N28b57c3137be44c8bbb2d5dbb2e44ac4
4 N295180e9e89e4d8eae21f4f1d18b8968
5 N3fd34d43aef746639c324793af461099
6 N6fc8f44b4c41468886de95a3c9de4743
7 N7d4f9a53eef948c9876e45b189fe1a2d
8 N98d002d1e63d4123b36942b359be941c
9 N9f31905979ac46f5aa0391434eede5f0
10 Na69b563e06af4083bc01ec369a05c2dc
11 Nb07a3c7b32784b6b9c5cb0e38b13611c
12 Nb72024e6df73417cadd01fed896b96e3
13 Nbdab306ac027470d96b63b89dbde6fb8
14 Nc75a62b10aaa484884f0cd74307880bf
15 Ncde625f33d354aa69cd5db3600194f13
16 Nd13cc054fe0f42698150788805d932ca
17 Ndb7821b7494349f5abff26eff2581e90
18 Nfed2fb7df3724a81ace62190d0723598
19 anzsrc-for:06
20 anzsrc-for:0601
21 schema:author N32db09d77ed74a1d874a623e1721fb19
22 schema:datePublished 1998-09
23 schema:datePublishedReg 1998-09-01
24 schema:description Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FTI-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for lack of toxicity to normal cells, cytotoxic versus cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N167a3b1c2ec548d48cbf7bdaa62751f8
29 N76e06aa5d2574d55a16d05f31a1548ca
30 sg:journal.1097543
31 schema:name Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
32 schema:pagination 1439
33 schema:productId N072640ed05a44ae5988e02ee7a44e0ff
34 Nc05275bec1db4d8eaebbe995381b4b0d
35 Nc781547d2617453e93b8f5501c5cfc96
36 Ncbd9e5e46afa4187847553ff096e45a6
37 Nda92feeaab4f4e46b50a6d9774485bd7
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025114095
39 https://doi.org/10.1038/sj.onc.1202175
40 schema:sdDatePublished 2019-04-11T12:03
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N6fbfcab15e624215a018129eb89f8b8f
43 schema:url https://www.nature.com/articles/1202175
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N072640ed05a44ae5988e02ee7a44e0ff schema:name pubmed_id
48 schema:value 9779989
49 rdf:type schema:PropertyValue
50 N07e02c34f74b48b8b20c7592cfa4fd42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Lymphokines
52 rdf:type schema:DefinedTerm
53 N167a3b1c2ec548d48cbf7bdaa62751f8 schema:issueNumber 11
54 rdf:type schema:PublicationIssue
55 N1e1c045b5cef4ddb8c8d2ccf9826b264 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name ras Proteins
57 rdf:type schema:DefinedTerm
58 N28b57c3137be44c8bbb2d5dbb2e44ac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Animals
60 rdf:type schema:DefinedTerm
61 N295180e9e89e4d8eae21f4f1d18b8968 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Enzyme Inhibitors
63 rdf:type schema:DefinedTerm
64 N32db09d77ed74a1d874a623e1721fb19 rdf:first sg:person.0645204112.22
65 rdf:rest N48a98a56cfb84322a7c89d8fe2fc291e
66 N3fd34d43aef746639c324793af461099 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Cell Adhesion
68 rdf:type schema:DefinedTerm
69 N48a98a56cfb84322a7c89d8fe2fc291e rdf:first sg:person.0651643165.04
70 rdf:rest rdf:nil
71 N6fbfcab15e624215a018129eb89f8b8f schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 N6fc8f44b4c41468886de95a3c9de4743 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Vascular Endothelial Growth Factor A
75 rdf:type schema:DefinedTerm
76 N76e06aa5d2574d55a16d05f31a1548ca schema:volumeNumber 17
77 rdf:type schema:PublicationVolume
78 N7d4f9a53eef948c9876e45b189fe1a2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name GTP-Binding Proteins
80 rdf:type schema:DefinedTerm
81 N98d002d1e63d4123b36942b359be941c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Farnesyltranstransferase
83 rdf:type schema:DefinedTerm
84 N9f31905979ac46f5aa0391434eede5f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Membrane Proteins
86 rdf:type schema:DefinedTerm
87 Na69b563e06af4083bc01ec369a05c2dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Neoplasms
89 rdf:type schema:DefinedTerm
90 Nb07a3c7b32784b6b9c5cb0e38b13611c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Alkyl and Aryl Transferases
92 rdf:type schema:DefinedTerm
93 Nb72024e6df73417cadd01fed896b96e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name rhoB GTP-Binding Protein
95 rdf:type schema:DefinedTerm
96 Nbdab306ac027470d96b63b89dbde6fb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Endothelial Growth Factors
98 rdf:type schema:DefinedTerm
99 Nc05275bec1db4d8eaebbe995381b4b0d schema:name dimensions_id
100 schema:value pub.1025114095
101 rdf:type schema:PropertyValue
102 Nc75a62b10aaa484884f0cd74307880bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Cell Line, Transformed
104 rdf:type schema:DefinedTerm
105 Nc781547d2617453e93b8f5501c5cfc96 schema:name nlm_unique_id
106 schema:value 8711562
107 rdf:type schema:PropertyValue
108 Ncbd9e5e46afa4187847553ff096e45a6 schema:name doi
109 schema:value 10.1038/sj.onc.1202175
110 rdf:type schema:PropertyValue
111 Ncde625f33d354aa69cd5db3600194f13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Vascular Endothelial Growth Factors
113 rdf:type schema:DefinedTerm
114 Nd13cc054fe0f42698150788805d932ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Actins
116 rdf:type schema:DefinedTerm
117 Nda92feeaab4f4e46b50a6d9774485bd7 schema:name readcube_id
118 schema:value 77a4f9ed3a6c919e3b9316677e8ebdff7fd98240e4bcac876681c6a4c41c3ce6
119 rdf:type schema:PropertyValue
120 Ndb7821b7494349f5abff26eff2581e90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 Nfed2fb7df3724a81ace62190d0723598 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Antineoplastic Agents
125 rdf:type schema:DefinedTerm
126 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
127 schema:name Biological Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
130 schema:name Biochemistry and Cell Biology
131 rdf:type schema:DefinedTerm
132 sg:journal.1097543 schema:issn 0950-9232
133 1476-5594
134 schema:name Oncogene
135 rdf:type schema:Periodical
136 sg:person.0645204112.22 schema:affiliation https://www.grid.ac/institutes/grid.251075.4
137 schema:familyName Lebowitz
138 schema:givenName Peter F
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645204112.22
140 rdf:type schema:Person
141 sg:person.0651643165.04 schema:affiliation https://www.grid.ac/institutes/grid.251075.4
142 schema:familyName Prendergast
143 schema:givenName George C
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651643165.04
145 rdf:type schema:Person
146 https://www.grid.ac/institutes/grid.251075.4 schema:alternateName Wistar Institute
147 schema:name The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
148 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...